Ansbert Gadicke

Ansbert is co-founder and Managing Director of MPM and its venture capital activities, as well as an investment committee member of MPM’s impact collaboration with UBS that is a public/private crossover vehicle managed by MPM. He and his partner, Luke Evnin, PhD, founded MPM in 1997. Ansbert and the MPM team have been the inspiration and driving force behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), Pharmasset (acquired by Gilead Sciences) and Radius Health. MPM believes that these companies, in which Ansbert was the lead investor and served on the boards, are some of the biggest successes in biotech history – companies that ultimately resulted in helping thousands of patients live longer and vastly improved lives. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and investment business from 1992 to 1997, and prior to that he was at The Boston Consulting Group in their Boston office. Both Ansbert and Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at Cullinan Oncology, NextPoint Therapeutics, Orna Therapeutics and TCR2 Therapeutics, and he serves as a Board Director at ElevateBio and iTeos Therapeutics. He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital. Ansbert received an MD from JW Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008).

Cerimon Pharmaceuticals

Denise Pollard-knight

Denise has been responsible for leading the Team's investment activities since joining in 1999 and has over 11 years experience as a venture capitalist. Prior to this she was an investment manager in the Bioscience Unit of Rothschild Asset Management, a group managing over $500 million in private and public biotechnology companies.Denise has held senior management positions in R&D and in strategic consulting. Denise holds a PhD and BSc (Hons) from Birmingham University and was a Fulbright Scholar at the University of California, Berkeley. She is also actively involved in US and European investments most recently Proteolix and OncoMed. She is currently a Director of Albireo, Cerimon, Idenix, Nabriva, and OncoMed and was previously a Director on the board of Viacell and DeveloGen and an observer on the board of Ark. Denise is a member of the Board of Trustees and Council of the British Heart Foundation and holds a Diploma in Company Direction from the Institute of Directors. Denise is a Director of Nomura Phase4 Ventures Ltd and a member of the Investment Committee.

Cerimon Pharmaceuticals

Vaughn Kailian

Vaughn Kailian joined MPM's Boston office in 2005 and brought to MPM unparalleled success in the stewardship of commercial biotech and pharmaceutical companies. From 2002 - 2004, he served as vice chair of the Board of Directors of Millennium Pharmaceuticals, Inc.

Cerimon Pharmaceuticals